Last updated: 2026-10-19 22:10:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Anteris Technologies Global Corp. (AVR) operates in the ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES sector and is listed on NASDAQ. The stock is currently priced at $6.18, with a market capitalization of $589.62M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.30 to $11.06. This page covers its latest market performance, valuation, price trends and company information.
$589.62M | |
$6.09 | |
$42.50 | |
$0.09 | |
$6.05 | |
920.95K | |
946.53K | |
-- | |
$11.06 | |
$3.30 | |
-- | |
-- |
Anteris Technologies Global Corp. (AVR) is trading at $6.18 in after-hours trading as of 2026-10-19 20:59:00, up 2.07% ($0.13) from the regular-session close of $6.05.
After-hours trading shows how investors are pricing AVR after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Anteris Technologies Global Corp. (AVR) moved from $6.63 to $6.18, representing a decline of 6.86% ($0.46).
The stock traded between $6.04 and $6.90 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.31 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 37.1%
AVR is currently trading at $6.18, placing it 37.1% of the way from its 52-week low of $3.30 to its 52-week high of $11.06. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
| Industry | ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES |
| Employees | 174 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Anteris Technologies Global Corp. (AVR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.